Private equity firm Blackstone is nearing a deal to sell Japanese supplement maker Alinamin Pharmaceutical to North Asian buyout fund MBK Partners for $2.17bn.The deal is expected to be signed soon, said the person, who declined to be identified as the information was private.
MBK, Blackstone and Alinamin declined to comment.
Blackstone had agreed in August 2020 to acquire Alinamin, then a subsidiary of Takeda Pharmaceutical according to an announcement from the private equity firm at the time.
Can’t stop reading? Read more
US Pipeline Operator ONEOK Inks Two Deals for $5.9 Billion
US pipeline operator ONEOK Inc. agreed to buy a Permian Basin rival and a controlling stake in...
Blackstone Is Said to Seek A$5.5 Billion Loan for AirTrunk Bid
Private equity firm Blackstone Inc. is in discussions with banks for a five-year loan of about...
Thrive Capital to lead multi-billion dollar OpenAI investment round at $100bn valuation
OpenAI, the company behind the popular AI tool ChatGPT, is in advanced talks to secure several...